Immutep targets 2H 2027 start for efti trials in PD-L1-negative head and neck cancer, soft tissue sarcoma

• Immutep reset efti’s registration strategy, prioritizing head and neck cancer in PD‑L1‑negative patients plus neoadjuvant soft tissue sarcoma.
• No new trial results were presented; the plan relies on previously reported positive signals in those settings.
• Development was redirected following TACTI-004’s early stop, with analysis pointing to manufacturing-related product differences as a likely driver.
• Preparations began for new studies targeted to start in 2H 2027, subject to trial design, regulators, manufacturing, funding, partnering.
• A new 200 L manufacturing run was contracted to return to the earlier product used in prior studies with more consistent immune activity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on September 11, 2026, and is solely responsible for the information contained therein.